DBV Technologies Raises $30 Million Through At-The-Market ADS Sale
DBV Technologies SA, a clinical-stage biopharmaceutical company, has announced the sale of approximately $30 million of American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. The new ordinary shares, issued in the form of ADSs, were sold to Artisan Partners Limited Partnership through Citizens Capital Markets as sales agent. This transaction will result in a dilution of approximately 5.96% for existing shareholders. Following this offering, the company estimates its cash runway is now extended to the end of the fourth quarter of 2026, providing sufficient funds to support operations for at least the next 12 months.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DBV Technologies SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001135835-en) on October 29, 2025, and is solely responsible for the information contained therein.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。